Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access

Abeona Therapeutics ( (ABEO) ) has provided an announcement.

Abeona Therapeutics said on March 9, 2026, that commercial momentum is building for ZEVASKYN, its FDA-approved autologous gene therapy for wounds in patients with recessive dystrophic epidermolysis bullosa, following optimization of a key release assay in 2025. Commercial launch activities began in the fourth quarter of 2025, with the first patient treated in December ahead of a scheduled facility shutdown, and additional patients have entered the treatment and manufacturing queue since operations resumed in late January 2026.

The company reported strengthening market access, with coverage policies in place at all major U.S. commercial insurers representing about 80 percent of commercially insured lives, as well as across all Medicaid programs, and noted that ZEVASKYN has been assigned a permanent CMS J-code effective January 1, 2026 to facilitate billing and reimbursement. Abeona highlighted growing familiarity among Qualified Treatment Centers and rising interest from patients and physicians, which together suggest that early positive treatment experiences and streamlined reimbursement could underpin sustained demand and reinforce the company’s position in the emerging gene therapy market for rare dermatologic diseases.

The most recent analyst rating on (ABEO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.

Spark’s Take on ABEO Stock

According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.

The score is held back mainly by weak operating performance and persistent cash burn despite a stronger balance sheet. Offsetting this, the latest earnings call reflected solid commercial and reimbursement progress for ZivaSkin, and technicals show modest near-term momentum, while valuation appears optically low but is tempered by earnings-quality concerns.

To see Spark’s full report on ABEO stock, click here.

More about Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with a fully integrated cGMP manufacturing facility in Cleveland, Ohio supporting commercial production. Its lead product, ZEVASKYN (prademagene zamikeracel), is the first and only autologous cell sheet-based gene therapy approved for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, and the company also advances an AAV-based gene therapy pipeline for ophthalmic and other high unmet-need conditions.

Abeona’s novel next-generation AAV capsids are being evaluated across a range of devastating diseases, underscoring its strategic focus on rare and severe disorders where existing treatment options are limited. The company positions itself as both a developer and manufacturer, leveraging in-house capabilities to support commercialization and potentially improve speed and control over its gene and cell therapy programs.

Average Trading Volume: 1,123,000

Technical Sentiment Signal: Strong Sell

Current Market Cap: $262.8M

For detailed information about ABEO stock, go to TipRanks’ Stock Analysis page.